tipifarnib has been researched along with Exanthem in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Balis, FM; Chow, C; Clark, G; Eng-Wong, J; Gantz, SB; Jayaprakash, N; Lebowitz, PF; Venzon, D; Widemann, BC; Zujewski, J | 1 |
Mardiak, J; Moore, M; Palmer, PA; Perez-Ruixo, JJ; Rosenberg, JE; Sahasrabudhe, D; Seigne, JD; Small, EJ; Vaughn, DJ; von der Maase, H | 1 |
2 trial(s) available for tipifarnib and Exanthem
Article | Year |
---|---|
A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Dose-Response Relationship, Drug; Exanthema; Farnesyltranstransferase; Fatigue; Female; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Neoplasm Metastasis; Quinolones; Tamoxifen; Treatment Outcome | 2005 |
A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Diarrhea; Enzyme Inhibitors; Exanthema; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neutropenia; Prospective Studies; Quinolones; Remission Induction; Urinary Bladder Neoplasms; Urologic Neoplasms; Urothelium | 2005 |